Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Therapeutic Innovations in CML: Reducing Toxicity w/ Optimized Frontline Dosing or Programmed Dose Reductions, New ABL1 TKI Asciminib Is Very Promising

14 views
November 18, 2019
Comments 0
Login to view comments. Click here to Login